Get to know our clinical trials
Open-label, multicenter phase Ib study to evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.
THE PURPOSE OF THIS STUDY IS TO TEST DIFFERENT DOSES OF MOSUNETUZUMAB TO SEE IF IT IS SAFE AND TO LEARN HOW THE BODY PROCESSES THE DRUG. MOSUNETUZUMAB WILL BE EVALUATED IN COMBINATION WITH PIRTOBRUTINIB, WHICH IS ANOTHER DRUG CURRENTLY USED TO TREAT CLL.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- OPEN-LABEL, MULTICENTER PHASE IB STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF MOSUNETUZUMAB IN COMBINATION WITH PIRTOBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA.
- Code EudraCT: 2024-514152-32-00
- Protocol number: BO45287
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.